--- schema_version: "secwatch.filing_event.v1" accession: "0001193805-22-001480" form_type: "8-K" ticker: "ARCT" cik: "0001768224" company_name: "Arcturus Therapeutics Holdings Inc." filed_at: "2022-11-04T23:59:59+00:00" generated_at: "2026-06-22T07:11:21.271839+00:00" event_type: "other_material" sentiment: "negative" materiality_score: 0.6 calibrated_materiality_score: 0.6 confidence: "high" source: SEC EDGAR --- # Arcturus: Janssen ends Hep B pact, Vietnam mfg deal terminated; ARCT-154 study extended ## Summary - Janssen terminated Hep B collaboration; effective in 60 days; no penalties. - Mutual termination of Vietnam COVID-19 vaccine manufacturing deals with Vinbiocare; no penalties. - New Study Support Agreement for ARCT-154 vaccine study; payments to Vinbiocare through Q1 2025 plus royalty. - Arcturus takes on financial responsibility for continuing clinical activities in Vietnam. ## SEC filing metadata - accession: 0001193805-22-001480 - form_type: 8-K - ticker: ARCT - cik: 0001768224 - company_name: Arcturus Therapeutics Holdings Inc. - filed_at: 2022-11-04T23:59:59+00:00 - event_type: other_material - sentiment: negative - materiality_score: 0.6 - calibrated_materiality_score: 0.6 - confidence: high - sec_items: 1.01, 1.02, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001480/0001193805-22-001480-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001480/e617791_8k-arcturus.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193805-22-001480 - JSON: https://secwatch.observer/filing/0001193805-22-001480.json - Plain text: https://secwatch.observer/filing/0001193805-22-001480.txt ## Key facts - Material Agreements Arcturus Therapeutics Holdings Inc. entered into Study Support Agreement with Vinbiocare Biotechnology Joint Stock Company valued at limited payments through Q1 2025; single digit percentage of net sales of ARCT-154 up to a capped am (effective 2022-10-31). - Action: entry - Counterparty: Vinbiocare Biotechnology Joint Stock Company - Value: limited payments through Q1 2025; single digit percentage of net sales of ARCT-154 up to a capped am - Effective: 2022-10-31 source text: On October 31, 2022, Arcturus Therapeutics, Inc. (“Arcturus”), a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., entered into a Study Support Agreement (the “Support Agreement”) with Vinbiocare Biotechnology Joint Stock Company (“Vinbiocare”), a company established under the laws of Vietnam. evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001480/0001193805-22-001480-index.htm - Material Agreements Arcturus Therapeutics Holdings Inc. terminated Research Collaboration and License Agreement with Janssen Pharmaceuticals, Inc. valued at terminated in its entirety for convenience; effective 60 days after notice; no penalties (effective 2022-10-31). - Action: termination - Agreement: collaboration - Counterparty: Janssen Pharmaceuticals, Inc. - Value: terminated in its entirety for convenience; effective 60 days after notice; no penalties - Effective: 2022-10-31 source text: On October 31, 2022, Arcturus received notice of termination from Janssen Pharmaceuticals, Inc. of the Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc. and Janssen Pharmaceuticals, Inc., dated October 18, 2017 (the “Janssen Agreement”). evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001480/0001193805-22-001480-index.htm - Material Agreements Arcturus Therapeutics Holdings Inc. terminated Framework Drug Substance Supply Agreement with Vinbiocare Research and Manufacture Joint Stock Company valued at terminated by mutual agreement; no penalties (effective 2022-10-31). - Action: termination - Agreement: supply - Counterparty: Vinbiocare Research and Manufacture Joint Stock Company - Value: terminated by mutual agreement; no penalties - Effective: 2022-10-31 source text: and (2) Framework Drug Substance Supply Agreement (the “Supply Agreement”), signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiocare Research and Manufacture Joint Stock Company, attached as Exhibit 10.33 to Arcturus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 10, 2021 (File No. 001-38942). evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001480/0001193805-22-001480-index.htm - Material Agreements Arcturus Therapeutics Holdings Inc. terminated Technology License and Technical Support Agreement with Vinbiocare Research and Manufacture Joint Stock Company valued at terminated by mutual agreement; no penalties (effective 2022-10-31). - Action: termination - Agreement: license - Counterparty: Vinbiocare Research and Manufacture Joint Stock Company - Value: terminated by mutual agreement; no penalties - Effective: 2022-10-31 source text: On October 31, 2022, Arcturus and Vinbiocare executed a letter agreement terminating the following agreements, effective October 31, 2022: (1) Technology License and Technical Support Agreement (the “License Agreement”), signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiocare Research and Manufacture Joint Stock Company, attached as Exhibit 10.32 to Arcturus’ Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed on August 10, 2021 (File No. 001-38942); evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001480/0001193805-22-001480-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.